Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Facilities Co-Ordinator

Established in 2000, LBIC provides a focus for life science activity in London, offering laboratory and office facilities as well as a virtual service to meet the needs of a wide range of organisations, from micro businesses to multi-national corporations. LBIC is owned and operated by the prestigious Royal Veterinary College (RVC), the UK’s largest and longest-established veterinary institution. LBIC will soon expand into an additional building to offer further opportunities for companies.

Coulter Partners secures industry-leading Chief Medical Officer for Solu Therapeutics

London, November 21, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the placement of Sergio Santillana, MD, MSc, MBA, as Chief Medical Officer (CMO).

Solu Therapeutics is a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas.

Commercialisation Manager

Main Purpose of the Job
The role of the Commercialisation Manager is to support the Head of BDI in delivering Knowledge Exchange, Commercialisation, and Impact Strategies. The successful applicant will bring their own experience, expertise and professional networks to help Earlham to deliver knowledge exchange activities and generate impact.

Medicilon delivers fast turnaround time to meet your FDA submission deadline for SEND Format Conversion

Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data conversion and provide a good environment for electronic data submission. In recent years, Medicilon SEND team helped customers complete many send data conversion projects within very tight timeline and filed timely with FDA.

J A Kemp Webinar: Medical Devices at the EPO – What Can I Claim?

Patents directed to medical devices can be of great commercial value. However, claims relating to medical devices can fall foul of the European patent office’s statutory exclusions of medical methods, so care needs to be taken both during drafting and prosecution at the EPO. This webinar will discuss some of the issues faced in applications relating to medical devices at the EPO, and provide guidance on how to optimise claim coverage.

Topics will include:

• An overview of EPO exclusions from patentability relevant to medical devices

Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens

  • Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae
  • PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects

Integrated Drug Discovery Webinar: Macrocycles: An Increasingly Popular Strategy in Drug Design

Join the Pharmaron team on December 5th at 8am PT / 11am ET / 4pm GMT for an in-depth exploration of macrocycles in drug design and discovery!

In this webinar, Mike Waring, Professor and Head of Medicinal Chemistry at Newcastle University, and Sébastien Campos, Senior Director of Medicinal Chemistry at Pharmaron, will explore how macrocycles are transforming the field. Discover key principles for rational macrocycle design and learn about the unique benefits and challenges of this compound class.

Stilla Technologies with Source BioScience Brings Advanced Genomics Solutions to the UK Market

Cambridge, UK – November 15, 2024 – Stilla Technologies, a global leader in digital PCR (dPCR) solutions, has announced a strategic partnership with Source BioScience, a leading UK-based genomics service provider. This collaboration will bring cutting-edge dPCR technology to the forefront of molecular genetics in the UK and Ireland, with Source BioScience becoming the first provider in the region to offer Stilla’s NIO system.

Subscribe to